RYR2 and cancer: The mutation frequency of the 19 genes was then validated using the Cancer Cell Line Encyclopedia (CCLE) dataset, thereby showing that five of the 19 genes (MUC12, MUC16, RIMS2, RYR2, and SPTA1) were more frequently mutated in the bortezomib-insensitive cell lines (Supplementary Table 4).